Stephen Jones STEPHEN JONES, US Oncology Research, Houston Long term data from an early breast cancer trial involving cyclophosphamide combined with docetaxel or doxorubicin have shown a survival adva
Stephen Jones
STEPHEN JONES, US Oncology Research, HoustonLong term data from an early breast cancer trial involving cyclophosphamide combined with docetaxel or doxorubicin have shown a survival advantage for the taxane. AsStephen Jonesof US Oncology Research explained to Derek Thorne, this advantage was also seen in patients over 65.
Tags
Related Episodes
Amparo Garcia-Tejedor MD, PhD; 2026 EBCC: Axillary Radiotherapy Seems As Effective as Axillary Lymphadenectomy in Sentinel Node Positive Early Breast Cancer, with Less Risk of Lymphedema
Axillary Radiotherapy Seems As Effective as Axillary Lymphadenectomy in Sentinel Node Positive Early Breast Cancer, with Less Risk of Lymphedema An interview with: Amparo Garcia-Tejedor MD, PhD, Profe
Eline Verreck BSc; 2026 EBCC: Radiation Boost May No Longer Be Justified After Standard Therapy for Early Breast Cancer
Radiation Boost May No Longer Be Justified After Standard Therapy for Early Breast Cancer An interview with: Eline Verreck BSc, Erasmus University Medical Centre, Surgical Oncology Department, Rotterd
Aditya Bardia MD MPH; 2025 San Antonio Breast Cancer Symposium: Selective Estrogen Degrader Giredestrant Improves on Standard Endocrine Therapy for Patients with ER-positive, HER2-negative Early Breast Cancer: Phase III lidERA Breast Cancer trial Findings
A seective estrogen degrader out-performed AI’s in ER+ HER- early breast cancer